메뉴 건너뛰기




Volumn 15, Issue 8, 2013, Pages 975-988

The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

1 TERT BUTYL 3 [6 (3, 5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO) PYRIDO [2, 3 D] PYRIMIDIN 7 YL] UREA; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 2; PONATINIB; UNCLASSIFIED DRUG;

EID: 84881039897     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121106     Document Type: Article
Times cited : (112)

References (54)
  • 1
    • 75149170979 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling: From development to cancer
    • Turner N and Grose R (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2), 116-129.
    • (2010) Nat Rev Cancer , vol.10 , Issue.2 , pp. 116-129
    • Turner, N.1    Grose, R.2
  • 2
    • 79959713140 scopus 로고    scopus 로고
    • Fibroblast growth factors and their receptors in cancer
    • Wesche J, Haglund K, and Haglund EM (2011). Fibroblast growth factors and their receptors in cancer. Biochem J 437(2), 199-213.
    • (2011) Biochem J , vol.437 , Issue.2 , pp. 199-213
    • Wesche, J.1    Haglund, K.2    Haglund, E.M.3
  • 3
    • 84859415553 scopus 로고    scopus 로고
    • Molecular pathways: Fibroblast growth factor signaling: A new therapeutic opportunity in cancer
    • Brooks AN, Kilgour E, and Smith PD (2012). Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 18(7), 1855-1862.
    • (2012) Clin Cancer Res , vol.18 , Issue.7 , pp. 1855-1862
    • Brooks, A.N.1    Kilgour, E.2    Smith, P.D.3
  • 4
    • 60549084927 scopus 로고    scopus 로고
    • Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: A novel class of receptor tyrosine kinase inhibitors
    • Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, et al. (2009). Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J Med Chem 52(2), 278-292.
    • (2009) J Med Chem , vol.52 , Issue.2 , pp. 278-292
    • Renhowe, P.A.1    Pecchi, S.2    Shafer, C.M.3    McHajewski, T.D.4    Jazan, E.M.5    Taylor, C.6    Antonios-McCrea, W.7    McBride, C.M.8    Frazier, K.9    Wiesmann, M.10
  • 7
    • 77952828838 scopus 로고    scopus 로고
    • Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis
    • Dey JH, Bianchi F, Voshol J, Bonenfant D, Oakeley EJ, and Hynes NE (2010). Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70(10), 4151-4162.
    • (2010) Cancer Res , vol.70 , Issue.10 , pp. 4151-4162
    • Dey, J.H.1    Bianchi, F.2    Voshol, J.3    Bonenfant, D.4    Oakeley, E.J.5    Hynes, N.E.6
  • 8
    • 81055124256 scopus 로고    scopus 로고
    • Targeting FGFR/PDGFR/ VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer
    • Taeger J, Moser C, Hellerbrand C, Mycielska ME, Glockzin G, Schlitt HJ, Geissler E. K, Stoeltzing O, and Lang SA (2011). Targeting FGFR/PDGFR/ VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther 10(11), 2157-2167.
    • (2011) Mol Cancer Ther , vol.10 , Issue.11 , pp. 2157-2167
    • Taeger, J.1    Moser, C.2    Hellerbrand, C.3    Mycielska, M.E.4    Glockzin, G.5    Schlitt, H.J.6    Geissler, E.K.7    Stoeltzing, O.8    Lang, S.A.9
  • 9
    • 15944378835 scopus 로고    scopus 로고
    • CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
    • Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, and Stewart AK (2005). CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood 105(7), 2941-2948.
    • (2005) Blood , vol.105 , Issue.7 , pp. 2941-2948
    • Trudel, S.1    Li, Z.H.2    Wei, E.3    Wiesmann, M.4    Chang, H.5    Chen, C.6    Reece, D.7    Heise, C.8    Stewart, A.K.9
  • 12
    • 36348943566 scopus 로고    scopus 로고
    • Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome
    • Chase A, Grand FH, and Cross NC (2007). Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 110(10), 3729-3734.
    • (2007) Blood , vol.110 , Issue.10 , pp. 3729-3734
    • Chase, A.1    Grand, F.H.2    Cross, N.C.3
  • 13
    • 78650875209 scopus 로고    scopus 로고
    • Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo
    • Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, and Knowles M. A (2011). Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer 104(1), 75-82.
    • (2011) Br J Cancer , vol.104 , Issue.1 , pp. 75-82
    • Lamont, F.R.1    Tomlinson, D.C.2    Cooper, P.A.3    Shnyder, S.D.4    Chester, J.D.5    Knowles, M.A.6
  • 14
    • 84862777035 scopus 로고    scopus 로고
    • A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets
    • Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, et al. (2012). A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61(5), 673-684.
    • (2012) Gut , vol.61 , Issue.5 , pp. 673-684
    • Deng, N.1    Goh, L.K.2    Wang, H.3    Das, K.4    Tao, J.5    Tan, I.B.6    Zhang, S.7    Lee, M.8    Wu, J.9    Lim, K.H.10
  • 15
    • 42249087301 scopus 로고    scopus 로고
    • A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    • Sarker D, Molife R, Evans TR, Hardie M, Marriott C, Butzberger-Zimmerli P, Morrison R., Fox JA, Heise C, Louie S, et al. (2008). A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin Cancer Res 14(7), 2075-2081.
    • (2008) Clin Cancer Res , vol.14 , Issue.7 , pp. 2075-2081
    • Sarker, D.1    Molife, R.2    Evans, T.R.3    Hardie, M.4    Marriott, C.5    Butzberger-Zimmerli, P.6    Morrison, R.7    Fox, J.A.8    Heise, C.9    Louie, S.10
  • 16
    • 0036566540 scopus 로고    scopus 로고
    • High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
    • Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch K. P, and Hughes TP (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99(9), 3472-3475.
    • (2002) Blood , vol.99 , Issue.9 , pp. 3472-3475
    • Branford, S.1    Rudzki, Z.2    Walsh, S.3    Grigg, A.4    Arthur, C.5    Taylor, K.6    Herrmann, R.7    Lynch, K.P.8    Hughes, T.P.9
  • 18
    • 49649127657 scopus 로고    scopus 로고
    • Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
    • Engelman JA and Janne PA (2008). Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10), 2895-2899.
    • (2008) Clin Cancer Res , vol.14 , Issue.10 , pp. 2895-2899
    • Engelman, J.A.1    Janne, P.A.2
  • 20
    • 33750302365 scopus 로고    scopus 로고
    • Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib
    • Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H., and Mitsudomi T (2006). Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12(19), 5764-5769.
    • (2006) Clin Cancer Res , vol.12 , Issue.19 , pp. 5764-5769
    • Kosaka, T.1    Yatabe, Y.2    Endoh, H.3    Yoshida, K.4    Hida, T.5    Tsuboi, M.6    Tada, H.7    Kuwano, H.8    Mitsudomi, T.9
  • 21
    • 84855503769 scopus 로고    scopus 로고
    • The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
    • Gibbons DL, Pricl S, Kantarjian H, Cortes J, and Quintas-Cardama A (2012). The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer 118(2), 293-299.
    • (2012) Cancer , vol.118 , Issue.2 , pp. 293-299
    • Gibbons, D.L.1    Pricl, S.2    Kantarjian, H.3    Cortes, J.4    Quintas-Cardama, A.5
  • 22
    • 53549104402 scopus 로고    scopus 로고
    • Activation of tyrosine kinases by mutation of the gatekeeper threonine
    • Azam M, Seeliger MA, Gray NS, Kuriyan J, and Daley GQ (2008). Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol 15(10), 1109-1118.
    • (2008) Nat Struct Mol Biol , vol.15 , Issue.10 , pp. 1109-1118
    • Azam, M.1    Seeliger, M.A.2    Gray, N.S.3    Kuriyan, J.4    Daley, G.Q.5
  • 23
    • 77953218598 scopus 로고    scopus 로고
    • Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: A 'head-to-head comparison'
    • Rosti G, Castagnetti F, Gugliotta G, Palandri F, Martinelli G, and Baccarani M (2010). Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'. Leuk Lymphoma 51(4), 583-591.
    • (2010) Leuk Lymphoma , vol.51 , Issue.4 , pp. 583-591
    • Rosti, G.1    Castagnetti, F.2    Gugliotta, G.3    Palandri, F.4    Martinelli, G.5    Baccarani, M.6
  • 24
    • 2642558897 scopus 로고    scopus 로고
    • Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
    • Blencke S, Zech B, Engkvist O, Greff Z, Orfi L, Horvath Z, Keri G, Ullrich A, and Daub H (2004). Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11(5), 691-701.
    • (2004) Chem Biol , vol.11 , Issue.5 , pp. 691-701
    • Blencke, S.1    Zech, B.2    Engkvist, O.3    Greff, Z.4    Orfi, L.5    Horvath, Z.6    Keri, G.7    Ullrich, A.8    Daub, H.9
  • 25
    • 25444460629 scopus 로고    scopus 로고
    • A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: Implications for clinical resistance in targeted cancer treatment
    • von Bubnoff N, Barwisch S, Speicher MR, Peschel C, and Duyster J (2005). A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment. Cell Cycle 4(3), 400-406.
    • (2005) Cell Cycle , vol.4 , Issue.3 , pp. 400-406
    • von Bubnoff, N.1    Barwisch, S.2    Speicher, M.R.3    Peschel, C.4    Duyster, J.5
  • 26
    • 33845360035 scopus 로고    scopus 로고
    • Ba/F3 cells and their use in kinase drug discovery
    • Warmuth M, Kim S, Gu XJ, Xia G, and Adrian F (2007). Ba/F3 cells and their use in kinase drug discovery. Curr Opin Oncol 19(1), 55-60.
    • (2007) Curr Opin Oncol , vol.19 , Issue.1 , pp. 55-60
    • Warmuth, M.1    Kim, S.2    Gu, X.J.3    Xia, G.4    Adrian, F.5
  • 27
  • 28
    • 66149152278 scopus 로고    scopus 로고
    • FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro
    • von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, and Duyster J (2009). FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 69(7), 3032-3041.
    • (2009) Cancer Res , vol.69 , Issue.7 , pp. 3032-3041
    • von Bubnoff, N.1    Engh, R.A.2    Aberg, E.3    Sanger, J.4    Peschel, C.5    Duyster, J.6
  • 29
    • 79952004905 scopus 로고    scopus 로고
    • The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro
    • von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thone S, Aberg E, Peschel C., and Duyster J (2011). The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 30(8), 933-943.
    • (2011) Oncogene , vol.30 , Issue.8 , pp. 933-943
    • von Bubnoff, N.1    Gorantla, S.P.2    Engh, R.A.3    Oliveira, T.M.4    Thone, S.5    Aberg, E.6    Peschel, C.7    Duyster, J.8
  • 30
    • 79960967335 scopus 로고    scopus 로고
    • A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients
    • Tiedt R, Degenkolbe E, Furet P, Appleton BA, Wagner S, Schoepfer J, Buck E, Ruddy D. A, Monahan JE, Jones MD, et al. (2011). A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res 71(15), 5255-5264.
    • (2011) Cancer Res , vol.71 , Issue.15 , pp. 5255-5264
    • Tiedt, R.1    Degenkolbe, E.2    Furet, P.3    Appleton, B.A.4    Wagner, S.5    Schoepfer, J.6    Buck, E.7    Ruddy, D.A.8    Monahan, J.E.9    Jones, M.D.10
  • 31
    • 54049122600 scopus 로고    scopus 로고
    • Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations
    • Avizienyte E, Ward RA, and Garner AP (2008). Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J 415(2), 197-206.
    • (2008) Biochem J , vol.415 , Issue.2 , pp. 197-206
    • Avizienyte, E.1    Ward, R.A.2    Garner, A.P.3
  • 32
    • 84859643082 scopus 로고    scopus 로고
    • Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
    • Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, and Sattler M (2012). Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia 26(4), 708-715.
    • (2012) Leukemia , vol.26 , Issue.4 , pp. 708-715
    • Deshpande, A.1    Reddy, M.M.2    Schade, G.O.3    Ray, A.4    Chowdary, T.K.5    Griffin, J.D.6    Sattler, M.7
  • 36
    • 34548250374 scopus 로고    scopus 로고
    • A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
    • Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, and Mohammadi M (2007). A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 27(5), 717-730.
    • (2007) Mol Cell , vol.27 , Issue.5 , pp. 717-730
    • Chen, H.1    Ma, J.2    Li, W.3    Eliseenkova, A.V.4    Xu, C.5    Neubert, T.A.6    Miller, W.T.7    Mohammadi, M.8
  • 39
    • 84889120137 scopus 로고
    • Improved methods for building protein models in electron density maps and the location of errors in these models
    • Jones TA, Zou JY, Cowan SW, and Kjeldgaard M (1991). Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(pt 2), 110-119.
    • (1991) Acta Crystallogr A , vol.47 , Issue.PART 2 , pp. 110-119
    • Jones, T.A.1    Zou, J.Y.2    Cowan, S.W.3    Kjeldgaard, M.4
  • 40
    • 84893482610 scopus 로고
    • A solution for the best rotation to relate two sets of vectors
    • Kabsch W (1976). A solution for the best rotation to relate two sets of vectors. Acta Crystallogr Sect A 32, 922-923.
    • (1976) Acta Crystallogr Sect A , vol.32 , pp. 922-923
    • Kabsch, W.1
  • 41
    • 0028103275 scopus 로고
    • The CCP4 suite: Programs for protein crystallography
    • Collaborative Computational Project, Number 4
    • Collaborative Computational Project, Number 4 (1994). The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(pt 5), 760-763.
    • (1994) Acta Crystallogr D Biol Crystallogr , vol.50 , Issue.PART 5 , pp. 760-763
  • 44
    • 5444250989 scopus 로고    scopus 로고
    • Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities
    • Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ, and Mohammadi M (2004). Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13(19), 2313-2324.
    • (2004) Hum Mol Genet , vol.13 , Issue.19 , pp. 2313-2324
    • Ibrahimi, O.A.1    Zhang, F.2    Eliseenkova, A.V.3    Itoh, N.4    Linhardt, R.J.5    Mohammadi, M.6
  • 45
    • 84857549430 scopus 로고    scopus 로고
    • FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features
    • Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ, and Pollock PM (2012). FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7(2), e30801.
    • (2012) PLoS One , vol.7 , Issue.2
    • Byron, S.A.1    Gartside, M.2    Powell, M.A.3    Wellens, C.L.4    Gao, F.5    Mutch, D.G.6    Goodfellow, P.J.7    Pollock, P.M.8
  • 46
    • 0038607097 scopus 로고    scopus 로고
    • The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum
    • Lievens PM and Liboi E (2003). The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. J Biol Chem 278(19), 17344-17349.
    • (2003) J Biol Chem , vol.278 , Issue.19 , pp. 17344-17349
    • Lievens, P.M.1    Liboi, E.2
  • 47
    • 5644241730 scopus 로고    scopus 로고
    • The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling
    • Lievens PM, Mutinelli C, Baynes D, and Liboi E (2004). The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling. J Biol Chem 279(41), 43254-43260.
    • (2004) J Biol Chem , vol.279 , Issue.41 , pp. 43254-43260
    • Lievens, P.M.1    Mutinelli, C.2    Baynes, D.3    Liboi, E.4
  • 49
    • 52049086201 scopus 로고    scopus 로고
    • Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation
    • Byron SA, Gartside MG, Wellens CL, Mallon MA, Keenan JB, Powell MA, Goodfellow P. J, and Pollock PM (2008). Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68(17), 6902-6907.
    • (2008) Cancer Res , vol.68 , Issue.17 , pp. 6902-6907
    • Byron, S.A.1    Gartside, M.G.2    Wellens, C.L.3    Mallon, M.A.4    Keenan, J.B.5    Powell, M.A.6    Goodfellow, P.J.7    Pollock, P.M.8
  • 51
    • 30144432781 scopus 로고    scopus 로고
    • Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain
    • Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH, Brandts C., Serve H, Roesel J, Giles F, et al. (2006). Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 107(1), 293-300.
    • (2006) Blood , vol.107 , Issue.1 , pp. 293-300
    • Heidel, F.1    Solem, F.K.2    Breitenbuecher, F.3    Lipka, D.B.4    Kasper, S.5    Thiede, M.H.6    Brandts, C.7    Serve, H.8    Roesel, J.9    Giles, F.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.